Four Decades for Justice
April 10, 2018
On April 10, 2018, Mylan N.V. (“Mylan”), a global pharmaceutical company, and Mapi Pharma Ltd. (“Mapi Pharma”), a fully integrated, clinical late stage biopharmaceutical company, announced that they will partner on the development and commercialization of GA Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis. Mylan is acquiring global marketing rights to the product. Cravath is representing Mylan in connection with the transaction.
The Cravath team is led by partners Aaron M. Gruber and Mark I. Greene and includes associate Alex L. Winkelman on M&A matters; partner David J. Kappos and associate Sean M. Gholz on intellectual property matters; and associate Damien J. Rose on tax matters.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.